Summary
The degree of binding to plasma proteins is an important determinant of drug disposition and response. Normal human pregnancy is associated with considerable changes in the concentration of plasma proteins, free fatty acids and possibly other endogenous substances interfering with drug binding. The possibility of an associated change in plasma binding capacity therefore needs to be taken into consideration.
Experimental studies conducted mostly in vitro have shown that the plasma protein binding of many (but not all) drugs is decreased during pregnancy, particularly during the last trimester. This phenomenon should be taken into account when interpreting serum concentrations of total (free + protein-bound) drug in clinical practice. Notable examples of drugs whose unbound fraction increases during pregnancy include diazepam, valproic acid, phenytoin, phenobarbitone, salicylic acid, pethidine, lignocaine, dexamethasone, sulphafurazole and propranolol.
For many drugs, important differences have been demonstrated in the degree of protein binding between maternal and cord plasma. In some cases, this may provide an explanation for the finding of marked differences in total drug concentration between maternal and fetal plasma at the time of delivery.
Similar content being viewed by others
References
Beckett, A.H. and Taylor, J.F.: Blood concentrations of pethidine and pentazocine in mother and infant at the time of birth. Journal of Pharmacy and Pharmacology 19 (Suppl.): 505–525 (1967).
Burt, R.L.: Plasma nonesterified fatty acids in normal pregnancy and puerperium. Obstetrics and Gynecology 15: 460–464 (1960).
Chen, S.-S.; Perucca, E.; Lee, J.-N.; Richens, A.: Serum protein binding and free concentration of phenytoin and phenobarbitone in pregnancy. British Journal of Clinical Pharmacology 13: 547–554 (1982).
Crawford, J.S. and Hooi, H.W.Y.: Binding of salicylic acid and sulphanilamide in serum from pregnant patients, cord blood and subjects taking oral contraceptives. British Journal of Anaesthesia 40: 825–833 (1968a).
Crawford, J.S. and Hooi, H.W.Y.: Binding of bromsulphthalein by serum albumin from pregnant women, neonates, and subjects on oral contraceptives. British Journal of Anaesthesia 40: 723–729 (1968b).
Crawford, J.S.; Davies, P. and Davies, P.: Further studies of the binding of bromsulphthalein by serum albumin. British Journal of Anaesthesia 43: 344–351 (1971).
Csogor, S.; Csutak, J. and Pressler, A.: Modifications of albumin transport capacity in pregnant women and newborn infants. Biology and Neonatalogy 13: 211–218 (1969).
Dam, M.; Christiansen, J.; Munck, O. and Mygind, K.I.: Anti-epileptic drugs: Metabolism in pregnancy. Clinical Pharmacokinetics 4: 53–62 (1979).
Davidsohn, I. and Henry, J.B.: Clinical Diagnosis by Laboratory Methods (Saunders, Philadelphia 1974).
Dean, M.; Stock, B.; Patterson, R.J. and Levy, G.: Serum protein binding of drugs during and after pregnancy in humans. Clinical Pharmacology and Therapeutics 28: 253–261 (1980).
Depp, R.; Kind, A.C.; Kirby, W.M. and Johnson, W.: Transplacental passage of methicillin and dicloxacillin into the fetus and amniotic fluid. American Journal of Obstetrics and Gynecology 107: 1054–1057 (1970).
Ehrnebo, M.; Agurell, S.; Jailing, B. and Boreus, L.O.: Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults. European Journal of Clinical Pharmacology 3: 189–193 (1971).
Gibaldi, M. and Koup, J.R.: Pharmacokinetic concepts. Drug binding, apparent volume of distribution and clearance. European Journal of Clinical Pharmacology 20: 299–306 (1981).
Gleichmann, W.; Bachmann, G.W.; Dengler, H.J. and Dudeck, J.: Effects of hormonal contraceptives and pregnancy on serum protein pattern. European Journal of Clinical Pharmacology 5: 218–225 (1973).
Gugler, R. and Von Unruh, G.E.: Clinical pharmacokinetics of valproic acid. Clinical Pharmacokinetics 5: 67–83 (1980).
Hamar, C. and Levy, G.: Serum protein binding of drugs and bilirubin in newborn infants and their mothers. Clinical Pharmacology and Therapeutics 28: 58–63 (1980a).
Hamar, C. and Levy, G.: Factors affecting the serum protein binding of salicylic acid in newborn infants and their mothers. Pediatric Pharmacology 1: 31–43 (1980b).
Hooper, W.D.; Bochner, F.; Eadie, M.J. and Tyrer, J.H.: Plasma protein binding of diphenylhydantoin. Effect of sex hormones, renal and hepatic disease. Clinical Pharmacology and Therapeutics 15: 277–282 (1974).
Kramer, B.; Kramer, F. and Hytten, F.E.: Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacology and Therapeutics 10: 301–328 (1980).
Lecomte, M.; Albeugres, E.; Huraux-Rendu, C. and Tillement, J.P.: Protein bound and free plasma phenytoin during pregnancy. Biological Research in Pregnancy 2: 95–98 (1981).
Levy, G.: Effect of plasma protein binding of drugs on duration and intensity of pharmacological activity. Journal of Pharmaceutical Sciences 65: 1264–1265 (1976).
Levy, G.; Procknal, J.A. and Garrettson, L.K.: Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium. Clinical Pharmacology and Therapeutics 18: 210–214 (1975).
Loughnan, P.M.; Greenwald, A. and Purton, W.W.: Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. Archives of Diseases in Childhood 52: 302–309 (1977).
MacDonald, H.N. and Good, W.: Changes in plasma total protein, albumin, urea and α-amino nitrogen concentrations in pregnancy and the puerperium. Journal of Obstetrics and Gynaecology of the British Commonwealth 78: 912–917 (1971).
Mandelli, M.; Morselli, P.L.; Nordio, S.; Pardi, G.; Principi, N.; Sereni, F. and Tognoni, G.: Placental transfer of diazepam and its disposition in the newborn. Clinical Pharmacology and Therapeutics 17: 564–572 (1975).
Mather, L.E. and Meffin, P.J.: Clinical pharmacokinetics of pethidine. Clinical Pharmacokinetics 3: 352–368 (1978).
Mather, L.E.; Long, G.J. and Thomas, J.: The binding of bupivacaine to maternal and foetal plasma proteins. Journal of Pharmacy and Pharmacology 23: 359–365 (1971).
Meyer, C.J.; Layne, D.S.; Tait, J.F. and Pincus, G.: The binding of aldosterone in normal, pregnant and steroid-treated women. Journal of Clinical Investigation 40: 1663–1671 (1961).
Moore, J.; McNabb, T.G. and McGlynn, J.P.: The placental transfer of pentazocine and pethidine. British Journal of Anaesthesia 45 (Suppl.): 798–801 (1973).
Moore, R.G. and McBride, W.G.: Disposition kinetics of diazepam in pregnant women at parturition. European Journal of Clinical Pharmacology 13: 275–284 (1978).
Morgan, D.J. and Thomas, J.: Plasma protein binding of etidocaine in pregnancy. Clinical and Experimental Pharmacology and Physiology 6: 197 (1979).
Morgan, D.J.; Cousins, M.; McQuillan, D. and Thomas, J.: Disposition and placental transfer of etidocaine in pregnancy. European Journal of Clinical Pharmacology 12: 359–365 (1977).
Morgan, D.J.; Moore, G.; Thomas, J. and Triggs, E.: Disposition of meperidine in pregnancy. Clinical Pharmacology and Therapeutics 23: 288–295 (1978).
Mygind, K.I.; Dam, M. and Christiansen, J.: Phenytoin and phenobarbital clearance during pregnancy. Acta Neurologica Scandinavica 54: 160–166 (1976).
Nation, R.L.: Meperidine binding in maternal and fetal plasma. Clinical Pharmacology and Therapeutics 29: 472–479 (1981).
Osathanondh, R.; Tulchinsky, D.; Kamali, H.; De Fendh, M. and Taeusch, H.W., Jr: Dexamethasone levels in treated pregnant women and newborn infants. Journal of Pediatrics 90: 617–620 (1977).
Perucca, E.: Plasma protein binding of phenytoin in health and disease: Relevance to therapeutic drug monitoring. Therapeutic Drug Monitoring 2: 331–344 (1980).
Perucca, E. and Richens, A.: Interpretation of serum drug levels-Relevance of plasma protein binding; in Drug Concentrations in Neuropsychiatry, pp.52–68 (Excerpta Medica, Amsterdam 1980).
Perucca, E.; Ruprah, M. and Richens, A.: Altered drug binding to serum proteins in pregnant women: Therapeutic relevance. Journal of the Royal Society of Medicine 74: 422–426 (1981a).
Perucca, E.; Ruprah, M. and Richens, A.: Decreased serum protein binding of diazepam and valproic acid in pregnant women. British Journal of Clinical Pharmacology 12: 276P (1981b).
Petersen, M.C.; Moore, R.G.; Nation, R.L. and McMeniman, W.: Relationship between the transplacental gradients of bupivacaine and α1-acid glycoprotein. British Journal of Clinical Pharmacology 12: 859–862 (1981).
Plasse, J.C.; Revol, M.; Mamelle, J.C. and Dutruge, J.: Protein binding of antiepileptic drugs in plasma during pregnancy and after delivery. XIth International Epilepsy Symposium, Florence, Abstract 4-67, p.168 (1979).
Porter, R.J. and Layzer, R.B.: Plasma albumin concentration and diphenylhydantoin binding in man. Archives of Neurology 32: 298–303 (1975).
Reboud, P.; Groulade, J.; Groslambert, P. and Colombo, M.: The influence of normal pregnancy and the postpartum state on plasma proteins and lipids. American Journal of Obstetrics and Gynecology 86: 820–828 (1963).
Roberts, R.K.; Desmond, P.V.; Wilkinson, G.R. and Shenker, S.: Disposition of chlordiazepoxide: Sex differences and effects of oral contraceptives. Clinical Pharmacology and Therapeutics 25: 826–831 (1979).
Routledge, P.A.; Stargel, W.W.; Kitchell, B.B.; Barchowsky, A. and Shand, D.G.: Sex related differences in the plasma protein binding of lignocaine and diazepam. British Journal of Clinical Pharmacology 11: 245–250 (1981).
Rowland, M.: Plasma protein binding and therapeutic drug monitoring. Therapeutic Drug Monitoring 2: 29–37 (1980).
Ruprah, M.; Perucca, E. and Richens, A.: Decreased serum protein binding of phenytoin in late pregnancy. Lancet 2: 316–317 (1980).
Ruprah, M.; Perucca, E. and Richens, A.: Phenytoin binding in pregnancy. Lancet 1: 97 (1981).
Shand, D.G.; Mitchell, J.R. and Oates, J.R.: Pharmacokinetic drug interactions; in Gillette and Mitchell (Eds) Concepts in Biochemical Pharmacology, pp.272–314 (Springer-Verlag, Berlin 1975).
Song, C.S.; Merkatz, I.R.; Rifking, A.B.; Gillette, P.N. and Kappas, A.; The influence of pregnancy and oral contraceptive steroids on the concentration of plasma proteins. American Journal of Obstetrics and Gynecology 108: 227–231 (1970).
Stock, B.; Dean, M. and Levy, G.: Serum protein binding of drugs during and after pregnancy in rats. Journal of Pharmacology and Experimental Therapeutics 212: 264–268 (1980).
Thomas, J.; Climie, C.R. and Mather, L.E.: The maternal plasma levels and placental transfer of bupivacaine following epidural anaesthesia. British Journal of Anaesthesia 41: 1035–1040 (1969).
Thomas, J.; Long, G.; Moore, G. and Morgan, D.: Plasma protein binding and placental transfer of bupivacaine. Clinical Pharmacology and Therapeutics 19: 426–434 (1976).
Tsuei, S.E.; Petersen, M.C.; Ashley, J.J.; McBride, W.G. and Moore, R.G.: Disposition of synthetic glucocorticoids. II. Dexamethasone in parturient women. Clinical Pharmacology and Therapeutics 28: 88–98 (1980).
Tucker, G.T. and Mather, L.E.: Pharmacokinetics of local anaesthetic agents. British Journal of Anaesthesiology 47 (Suppl.): 213–224 (1975).
Tucker, G.T.; Boyes, R.N. and Bridenbaugh, P.O.: Binding of anilide-type local anaesthetics in human plasma. II. Implications in vivo, with special reference to transplacental distribution. Anesthesiology 33: 304–314 (1970).
Wiegand, U.W. and Levy, G.: Effect of heparin injection on the plasma protein binding of bilirubin and salicylate in rats. Journal of Pharmaceutical Sciences 68: 1483–1486 (1979).
Wood, M. and Wood, A.J.J.: Changes in plasma drug binding and α1-acid glycoprotein in mother and newborn infant. Clinical Pharmacology and Therapeutics 29: 522–526 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perucca, E., Crema, A. Plasma Protein Binding of Drugs in Pregnancy. Clin Pharmacokinet 7, 336–352 (1982). https://doi.org/10.2165/00003088-198207040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198207040-00004